Scotia Biologics

Executive Summary

Scotia Biologics is a Glasgow-based antibody engineering service provider founded in 2015. The company offers custom antibody generation tailored to specific research targets, enabling scientists to bypass lengthy catalog and polyclonal antibody sourcing. By delivering high-quality, target-specific antibodies faster than traditional routes, Scotia Biologics supports accelerated preclinical validation and research progress. Its service model reduces the months typically wasted on unsuitable reagents, making it a valuable partner for academic and biopharma research teams. While the company operates in a competitive contract research space, its focus on engineering expertise and custom solutions differentiates it from larger reagent suppliers. With no disclosed funding rounds or pipeline, Scotia Biologics remains a niche but essential player in the antibody tools market.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation antibody engineering platform70% success
• Q2 2027Strategic partnership with a major pharma company for custom antibody services50% success
• Q1 2027Expansion into the US market through a distribution agreement60% success